Developments in pediatric psychopharmacology: Focus on stimulants, antidepressants, and antipsychotics

Journal of Clinical Psychiatry

Volumn 72, Issue 5, 2011, Pages 655-670

  Correll, Christoph U ^a,b,c,d   Kratochvil, Christopher J ^e   March, John S ^f  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; ATOMOXETINE; CENTRAL STIMULANT AGENT; CITALOPRAM; CLONIDINE; CLOZAPINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; GUANFACINE; HALOPERIDOL; ILOPERIDONE; INTUNIV; LITHIUM CARBONATE; LURASIDONE; METHYLPHENIDATE; MIRTAZAPINE; MOLINDONE; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PAROXETINE; PEMOLINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ADOLESCENCE; AGITATION; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; BEHAVIOR THERAPY; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR MANIA; CHILDHOOD; COGNITIVE THERAPY; CONDUCT DISORDER; CRABBINESS; CRYING; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSKINESIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; GENERALIZED ANXIETY DISORDER; GILLES DE LA TOURETTE SYNDROME; HUMAN; INSOMNIA; IRRITABILITY; LOW DRUG DOSE; MAJOR DEPRESSION; MANIA; MENTAL DEFICIENCY; METABOLIC DISORDER; MIXED MANIA AND DEPRESSION; MONOTHERAPY; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; OPPOSITIONAL DEFIANT DISORDER; OPTIMAL DRUG DOSE; PATIENT MONITORING; PEDIATRICS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; PSYCHOSOCIAL CARE; RESTLESSNESS; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOCIAL PHOBIA; SUICIDE; WEIGHT GAIN;

ADOLESCENT; AGE FACTORS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISTIC DISORDER; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DEPRESSIVE DISORDER, MAJOR; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 79959252898     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11r07064     Document Type: Review

References (149)

1. Chang K. Challenges in the diagnosis and treatment of pediatric bipolar depression. Dialogues Clin Neurosci. 2009;11(1):73-80. PubMed
2. Perlis RH, Miyahara S, Marangell LB, et al; STEP-BD Investigators. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry. 2004;55(9):875-881. doi:10.1016/j.biopsych. 204.01.02 PubMed
3. Kumra S, Oberstar JV, Sikich L, et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull. 2008;34(1):60-71. doi:10.1093/schbul/sbm109 PubMed (Pubitemid 350262286)
4. Perlis RH, Dennehy EB, Miklowitz DJ, et al. Retrospective age at onset of bipolar disorder and outcome during two-year follow-up: results from the STEP-BD study. Bipolar Disord. 2009;11(4):391-400. doi:10.1/j.139-5618.209.0686. x PubMed
5. Olfson M, Crystal S, Gerhard T, et al. Mental health treatment received by youths in the year before and after a new diagnosis of bipolar disorder. Psychiatr Serv. 2009;60(8):1098-1106. doi:10.176/api.ps.60.8.1098 PubMed
6. Moreno C, Laje G, Blanco C, et al. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry. 2007;64(9):1032-1039. doi:10.101/archpsyc.64.9.1032 PubMed (Pubitemid 47360848)
7. Blader JC, Carlson GA. Increased rates of bipolar disorder diagnoses among US child, adolescent, and adult inpatients, 1996-2004. Biol Psychiatry. 2007;62(2):107-114. doi:10.1016/j.biopsych.206.1.06 PubMed
8. Cooper WO, Hickson GB, Fuchs C, et al. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med. 2004;158(8):753-759. doi:10.101/archpedi.158.8.753 PubMed (Pubitemid 39025073)
9. Cooper WO, Arbogast PG, Ding H, et al. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr. 2006;6(2):79-83. doi:10.1016/j.ambp.205.1.02 PubMed (Pubitemid 43960577)
10. Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63(6):679-685. doi:10.101/archpsyc.63.6.679 PubMed (Pubitemid 43848299)
11. Olfson M, Crystal S, Huang C, et al. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry. 2010;49(1):13-23. PubMed
12. Patel NC, Sanchez RJ, Johnsrud MT, et al. Trends in antipsychotic use in a Texas Medicaid population of children and adolescents: 1996 to 2000. J Child Adolesc Psychopharmacol. 2002;12(3):221-229. doi:10.1089/10454602760386905 PubMed
13. Zito JM, Safer DJ, de Jong-van den Berg LT, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health. 2008;2(1):26. doi:10.186/1753-20-2-26 PubMed
14. Zito JM, Safer DJ, DosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med. 2003;157(1):17-25. PubMed
15. Zito JM, Safer DJ, Sai D, et al. Psychotropic medication patterns among youth in foster care. Pediatrics. 2008;121(1):e157-e163. doi:10.1542/peds.207- 0212 PubMed
16. Zito JM, Tobi H, de Jong-van den Berg LT, et al. Antidepressant prevalence for youths: a multi-national comparison. Pharmacoepidemiol Drug Saf. 2006;15(11):793-798. doi:10.102/pds.1254 PubMed
17. Gerhard T, Chavez B, Olfson M, et al. National patterns in the outpatient pharmacological management of children and adolescents with autism spectrum disorder. J Clin Psychopharmacol. 2009;29(3):307-310. doi:10.1097/JCP. 0b013e3181a20c8a PubMed
18. Crystal S, Olfson M, Huang C, et al. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood). 2009;28(5):w770-w781. doi:10.137/hlthaf.28.5.w70 PubMed
19. Correll CU, Penzner JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2006;15(1):177-206. doi:10.1016/j.chc.205.08. 07 PubMed (Pubitemid 41735243)
20. Ryan ND, Varma D. Child and adolescent mood disorders - experience with serotonin-based therapies. Biol Psychiatry. 1998;44(5):336-340. doi:10.1016/S06-323(98)0163-2 PubMed (Pubitemid 28432644)
21. Massanari M, Novitsky J, Reinstein LJ. Paradoxical reactions in children associated with midazolam use during endoscopy. Clin Pediatr (Phila). 1997;36(12):681-684. doi:10.17/09289703601202 PubMed (Pubitemid 27527875)
22. Kanegaye JT, Favela JL, Acosta M, et al. High-dose rectal midazolam for pediatric procedures: a randomized trial of sedative efficacy and agitation. Pediatr Emerg Care. 2003;19(5):329-336. doi:10.1097/01.pec.092578.40174.85 PubMed (Pubitemid 37323085)
23. Paxton JW, Dragunow M. Pharmacology. In: Werry JS, Aman MG, eds. Practitioner's Guide to Psychoactive Drugs for Children and Adolescents. New York, NY: Plenum Medical; 1993:23-55.
24. Safer DJ, Zito JM. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol. 2006;16(1-2):159-169. doi:10.1089/cap.206.16.159 PubMed
25. Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(1):9-20. doi:10.1097/chi.0b013e31815b5cb1 PubMed
26. Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010;12(2):116-141. doi:10.1/j.139-5618.2010.0798.x PubMed
27. Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry. 2009;166(9):992-1001. doi:10.176/api.ajp.209.09040472 PubMed
28. Winterstein AG, Gerhard T, Shuster J, et al. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/ hyperactivity disorder. Pediatrics. 2007;120(6):e1494-e1501. doi:10.1542/peds.207-0675 PubMed (Pubitemid 350223669)
29. Gerhard T, Winterstein AG, Olfson M, et al. Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD. Pharmacoepidemiol Drug Saf. 2010;19(5):457-464. PubMed
30. Wigal T, Greenhill L, Chuang S, et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1294-1303. doi:10.1097/01.chi.0235082.63156.27 PubMed (Pubitemid 44665446)
31. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297(15):1683-1696. doi:10.101/jama.297.15.1683 PubMed
32. de Leon J, Nikoloff DM. Paradoxical excitation on diphenhydramine may be associated with being a CYP2D6 ultrarapid metabolizer: three case reports. CNS Spectr. 2008;13(2):133-135. PubMed
33. DeVeaugh-Geiss J, March J, Shapiro M, et al. Child and adolescent psychopharmacology in the new millennium: a workshop for academia, industry, and government. J Am Acad Child Adolesc Psychiatry. 2006; 45(3):261-270. doi:10.1097/01.chi.0194568.70912.e PubMed
34. May DE, Kratochvil CJ. Attention-deficit hyperactivity disorder: recent advances in pediatric pharmacotherapy. Drugs. 2010;70(1):15-40. doi:10.2165/1530540-0-0 PubMed
35. March JS, Silva SG, Compton S, et al. The case for practical clinical trials in psychiatry. Am J Psychiatry. 2005;162(5):836-846. doi:10.176/api.ajp. 162.5.836 PubMed (Pubitemid 40676194)
36. Greenhill LL, Vitiello B, Riddle MA, et al. Review of safety assessment methods used in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2003;42(6):627-633. doi:10.1097/01.CHI.046841.56865.37 PubMed (Pubitemid 39625047)
37. dosReis S, Zito JM, Safer DJ, et al. Multiple psychotropic medication use for youths: a two-state comparison. J Child Adolesc Psychopharmacol. 2005;15(1):68-77. doi:10.1089/cap.205.15.68 PubMed
38. Bhangoo RK, Lowe CH, Myers FS, et al. Medication use in children and adolescents treated in the community for bipolar disorder. J Child Adolesc Psychopharmacol. 2003;13(4):515-522. doi:10.1089/104546032724904 PubMed (Pubitemid 38174241)
39. March JS, Silva SG, Compton S, et al. The case for practical clinical trials in psychiatry. Am J Psychiatry. 2005;162(5):836-846. doi:10.176/api.ajp. 162.5.836 PubMed (Pubitemid 40676194)
40. Greenhill LL, Vitiello B, Riddle MA, et al. Review of safety assessment methods used in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2003;42(6):627-633. doi:10.1097/01.CHI.046841.56865.37 PubMed (Pubitemid 39625047)
41. Greenhill LL, Vitiello B, Abikoff H, et al. Developing methodologies for monitoring long-term safety of psychotropic medications in children: report on the NIMH conference, September 25, 2000. J Am Acad Child Adolesc Psychiatry. 2003;42(6):651-655. doi:10.1097/01.CHI.046842.56865.EC PubMed (Pubitemid 39625050)
42. Vitiello B, Riddle MA, Greenhill LL, et al. How can we improve the assessment of safety in child and adolescent psychopharmacology? J Am Acad Child Adolesc Psychiatry. 2003;42(6):634-641. doi:10.1097/01.CHI.046840.90931.36 PubMed
43. Correll CU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse effects in children and adolescents. Int Rev Psychiatry. 2008;20(4):195-201. doi:10.1080/0954026080189179 PubMed (Pubitemid 351489515)
44. Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63(6):679-685. doi:10.101/archpsyc.63.6.679 PubMed (Pubitemid 43848299)
45. March J, Kratochvil C, Clarke G, et al. AACAP 2002 research forum: placebo and alternatives to placebo in randomized controlled trials in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2004; 43(8):1046-1056. doi:10.1097/01.chi.0129606.83206.7 PubMed
46. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
47. Barkley RA, Fischer M, Edelbrock CS, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: I. an 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1990;29(4):546-557. doi:10.1097/04583-19070-07 PubMed (Pubitemid 20235340)
48. Barkley RA, Fischer M, Smallish L, et al. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol. 2002;111(2):279-289. doi:10.1037/021-843X.1.2.279 PubMed (Pubitemid 34441206)
49. Biederman J, Faraone S, Milberger S, et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry. 1996;53(5):437-446. PubMed
50. Adler LA, Sutton VK, Moore RJ, et al. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. J Clin Psychopharmacol. 2006;26(6):648-652. doi:10.1097/01.jcp. 0239797.21826.70 PubMed (Pubitemid 44772744)
51. Vaughan BS, March JS, Kratochvil CJ. The evidence-based pharmacological treatment of paediatric ADHD. Int J Neuropsychopharmacol. 2011;1-13. doi:10.1017/S14614571095 PubMed
52. Faraone SV. Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. P T. 2009;34(12):678-694. PubMed
53. Biederman J, Melmed RD, Patel A, et al; SPD503 Study Group. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73-e84. doi:10.1542/peds.206-3695 PubMed
54. Sallee FR, McGough J, Wigal T, et al: SPD503 STUDY GROUP. Guanfacine extended release in children and adolescents with attention-deficit/ hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155-165. doi:10.1097/CHI.0b013e318191769e PubMed
55. Pliszka SR. Non-stimulant treatment of attention-deficit/hyperactivity disorder. CNS Spectr. 2003;8(4):253-258. PubMed
56. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073-1086. doi:10.101/archpsyc.56.12.1073 PubMed
57. Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry. 2007;46(8):989-1002. doi:10.1097/CHI.0b013e3180686d48 PubMed (Pubitemid 47220683)
58. Molina BS, Hinshaw SP, Swanson JM, et al; MTA Cooperative Group. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):484-500. doi:10.1097/CHI.0b013e31819c23d0 PubMed
59. Klein RG, Abikoff H, Hechtman L, et al. Design and rationale of controlled study of long-term methylphenidate and multimodal psychosocial treatment in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2004;43(7):792-801. doi:10.1097/01.chi.0128798.91601.fe PubMed (Pubitemid 38808484)
60. Abikoff H, Hechtman L, Klein RG, et al. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry. 2004;43(7):802-811. doi:10.1097/01.chi.0128791.1014.ac PubMed (Pubitemid 38808485)
61. Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1284-1293. doi:10.1097/01.chi.023507. 3261.61 PubMed (Pubitemid 44665445)
62. Abikoff HB, Vitiello B, Riddle MA, et al. Methylphenidate effects on functional outcomes in the Preschoolers with Attention-deficit/hyperactivity disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol. 2007;17(5):581-592. doi:10.1089/cap.207.068 PubMed (Pubitemid 350058982)
63. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921. doi:10.1097/chi.0b013e318054e724 PubMed
64. Pappadopulos E, Woolston S, Chait A, et al. Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. J Can Acad Child Adolesc Psychiatry. 2006;15(1):27-39. PubMed
65. Connor DF, Glatt SJ, Lopez ID, et al. Psychopharmacology and aggression. I: a meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry. 2002;41(3):253-261. doi:10.1097/04583-202030-04 PubMed
66. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54(11):1031-1037. PubMed
67. March J, Silva S, Petrycki S, et al; Treatment for Adolescents With Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004;292(7):807-820. doi:10.101/jama.292.7.807 PubMed
68. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002;41(10):1205-1215. doi:10.1097/04583-20210-010 PubMed (Pubitemid 38338040)
69. Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA. 2004;292(16):1969-1976. doi:10.101/jama.292. 16.1969 PubMed
70. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med. 2001;344(17):1279-1285. doi:10.1056/NEJM2010426341703 PubMed
71. Compton SN, Walkup JT, Albano AM, et al. Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methods. Child Adolesc Psychiatry Ment Health. 2010;4(1):1. doi:10.186/1753-20-4-1 PubMed
72. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008;359(26):2753-2766. doi:10.1056/NEJMoa080463 PubMed
73. March JS, Vitiello B. Clinical messages from the Treatment for Adolescents With Depression Study (TADS). Am J Psychiatry. 2009;166(10):1118- 1123. doi:10.176/api.ajp.209.08101606 PubMed
74. Curry J, Rohde P, Simons A, et al; TADS Team. Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006;45(12):1427-1439. doi:10.1097/01.chi. 0240838.78984.e2 PubMed (Pubitemid 44900916)
75. Treatment for Adolescents with Depression Study (TADS) Team. The Treatment for Adolescents With Depression Study (TADS): demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry. 2005;44(1):28-40. doi:10.1097/01.chi.0145807.09027.82 PubMed
76. Kratochvil CJ, May DE, Silva SG, et al. Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study. J Child Adolesc Psychopharmacol. 2009;19(5):519-527. doi:10.1089/cap.208.0143 PubMed
77. Emslie G, Kratochvil C, Vitiello B, et al; TADS Team. Treatment for Adolescents with Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry. 2006;45(12):1440-1455. doi:10.1097/01.chi.0240840.63737.1d PubMed (Pubitemid 44900917)
78. Vitiello B, Silva SG, Rohde P, et al. Suicidal events in the Treatment for Adolescents With Depression Study (TADS). J Clin Psychiatry. 2009;70(5):741-747. doi:10.408/JCP.08m04607 PubMed
79. March JS, Silva S, Petrycki S, et al; The TADS Team. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007;64(10):1132-1143. doi:10.101/archpsyc.64.10. 132 PubMed
80. Kennard BD, Silva SG, Tonev S, et al. Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes. J Am Acad Child Adolesc Psychiatry. 2009;48(2):186-195. doi:10.1097/CHI.0b013e31819176f9 PubMed
81. March J, Silva S, Curry J, et al; Treatment for Adolescents With Depression Study (TADS) Team. The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. Am J Psychiatry. 2009;166(10):1141-1149. doi:10.176/api.ajp.209.081620 PubMed
82. Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA. 2008;299(8):901-913. doi:10.101/jama.29.8.901 PubMed (Pubitemid 351397065)
83. Vitiello B. Combined cognitive-behavioural therapy and pharmacotherapy for adolescent depression: does it improve outcomes compared with monotherapy? CNS Drugs. 2009;23(4):271-280. doi:10.2165/023210-20923040-01 PubMed
84. Emslie GJ, Mayes T, Porta G, et al. Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes. Am J Psychiatry. 2010;167(7):782-791. doi:10.176/api.ajp.2010.0904052 PubMed
85. Vitiello B, Emslie G, Clarke G, et al. Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample. J Clin Psychiatry. 2011;72(3):388-396. doi:10.408/JCP.09m0585blu PubMed
86. Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164(7):1035-1043. doi:10.176/api.ajp.164.7.1035 PubMed (Pubitemid 47121392)
87. March JS, Klee BJ, Kremer CM. Treatment benefit and the risk of suicidality in multicenter, randomized, controlled trials of sertraline in children and adolescents. J Child Adolesc Psychopharmacol. 2006;16(1-2):91-102. doi:10.1089/cap.206.16.91 PubMed
88. Brent DA, Greenhill LL, Compton S, et al. The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. J Am Acad Child Adolesc Psychiatry. 2009;48(10):987-996. doi:10.1097/CHI.0b013e3181b5dbe4 PubMed
89. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3):332-339. doi:10.101/archpsyc.63.3.32 PubMed (Pubitemid 43345358)
90. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry. 2007;164(9):1356-1363. doi:10.176/api.ajp.207. 07030454 PubMed (Pubitemid 47461135)
91. Gibbons RD, Hur K, Bhaumik DK, et al. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry. 2005;62(2):165-172. doi:10.101/archpsyc.62.2.165 PubMed (Pubitemid 40189132)
92. Blader JC, Carlson GA. Increased rates of bipolar disorder diagnoses among US child, adolescent, and adult inpatients, 1996-2004. Biol Psychiatry. 2007;62(2):107-114. doi:10.1016/j.biopsych.206.1.06 PubMed
93. Pathak P, West D, Martin BC, et al. Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. Psychiatr Serv. 2010;61(2):123-129. doi:10.176/api.ps.61.2.123 PubMed
94. Wilson D. Poor children likelier to get antipsychotics. New York Times. December 11, 2009. http://www.nytimes.com/2009/12/12/health/12medicaid.html? pagewanted=all. Accessed April 15, 2011.
95. Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(1):9-20. doi:10.1097/chi.0b013e31815b5cb1 PubMed
96. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-1773. doi:10.101/jama.209.1549 PubMed
97. Vitiello B, Correll C, van Zwieten-Boot B, et al. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 2009;19(9):629-635. doi:10.1016/j.euroneuro. 209.04.08 PubMed
98. Jensen PS, Buitelaar J, Pandina GJ, et al. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. Eur Child Adolesc Psychiatry. 2007;16(2):104-120. doi:10.107/s0787-06-0580-1 PubMed (Pubitemid 46643895)
99. Findling RL, Kline K, Mckenna K, et al. Efficacy and safety of quetiapine in adolescents with schizophrenia: a 6-week, double-blind, randomized, placebo-controlled trial. Presented at: 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 28-November 2, 2008; Chicago, IL.
100. Findling RL, Cavus I, Pappadopulos E, et al. Efficacy and safety of ziprasidone in adolescents with schizophrenia. Presented at: 2nd Biannual Meeting of the Schizophrenia International Research Society (SIRS); April 10-14, 2010; Venice, Italy.
101. Haas M, Eerdekens M, Kushner S, et al. Efficacy, safety and tolerability of two risperidone dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry. 2009;194(2):158-164. doi:10.192/bjp.bp.107.04617 PubMed
102. Singh V, Vijapurkar U, Robb A, et al. Efficacy, safety and tolerability of paliperidone ER in adolescent patients with schizophrenia. Poster presented at: 65th Annual Meeting of the Society of Biological Psychiatry; May 20-22, 2010; New Orleans, LA.
103. Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. 2004;29(1):133-145. doi:10.1038/sj.np. 130327 PubMed (Pubitemid 38068023)
104. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. Am J Psychiatry. 2008;165(11):1420-1431. doi:10.176/api.ajp.208.08050756 PubMed
105. Arango C, Robles O, Parellada M, et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry. 2009;18(7):418-428. doi:10.107/s0787-09-0749-5 PubMed
106. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996;53(12):1090-1097. PubMed
107. Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006;63(7):721-730. doi:10.101/archpsyc.63.7.721 PubMed
108. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry. 2008;63(5):524-529. doi:10.1016/j.biopsych.207.04.043 PubMed (Pubitemid 351220784)
109. Delbello MP, Schwiers ML, Rosenberg HL, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002;41(10):1216-1223. doi:10.1097/04583-20210-01 PubMed (Pubitemid 38338041)
110. DelBello MP, Kowatch RA, Adler CM, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2006;45(3):305-313. doi:10.1097/01.chi.0194567.63289.97 PubMed
111. Pavuluri MN, Henry DB, Findling RL, et al. Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar Disord. 2010;12(6):593-605. doi:10.1/j.139-5618.2010.0850.x PubMed
112. McDougle CJ, Stigler KA, Erickson CA, et al. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry. 2008;69(suppl 4):15-20. PubMed
113. McCracken JT, McGough J, Shah B, et al; Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314-321. doi:10.1056/NEJMoa013171 PubMed
114. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5):e634-e641. doi:10.1542/peds. 203-0264-F PubMed (Pubitemid 41647671)
115. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol. 2006;21(6):450-455. PubMed
116. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110-1119. doi:10.1097/CHI.0b013e3181b7658 PubMed
117. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533-1540. doi:10.1542/peds.208-3782 PubMed
118. Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2006;16(5):541-548. doi:10.1089/cap.206.16.541 PubMed (Pubitemid 44737209)
119. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry. 2005;162(7):1361-1369. doi:10.176/api.ajp.162.7.1361 PubMed
120. Troost PW, Lahuis BE, Steenhuis MP, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry. 2005;44(11):1137- 1144. doi:10.1097/01.chi.01705.129.76 PubMed (Pubitemid 41508125)
121. Aman MG, McDougle CJ, Scahill L, et al; the Research Units on Pediatric Psychopharmacology Autism Network. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2009;48(12):1143-1154. doi:10.1097/CHI.0b013e3181bfd69 PubMed
122. Aman MG, De Smedt G, Derivan A, et al; Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002;159(8):1337-1346. doi:10.176/api.ajp.159.8.137 PubMed (Pubitemid 34832715)
123. Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry. 2007;46(5):558-565. doi:10.1097/chi.0b013e318032354 PubMed (Pubitemid 46642572)
124. Snyder R, Turgay A, Aman M, et al; Risperidone Conduct Study Group. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002;41(9):1026-1036. doi:10.1097/04583-202090-02 PubMed (Pubitemid 38338050)
125. Van Bellinghen M, De Troch C. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol. 2001;11(1):5-13. doi:10.1089/1045460175014348 PubMed (Pubitemid 32295178)
126. Findling RL, McNamara NK, Branicky LA, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry. 2000;39(4):509-516. doi:10.1097/04583-2040-021 PubMed (Pubitemid 30185547)
127. Greenhill LL, Solomon M, Pleak R, et al. Molindone hydrochloride treatment of hospitalized children with conduct disorder. J Clin Psychiatry. 1985;46(8, Pt 2):20-25. PubMed
128. Reyes M, Buitelaar J, Toren P, et al. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry. 2006;163(3):402-410. doi:10.176/api.ajp.163.3.402 PubMed (Pubitemid 44469381)
129. Wilson SJ, Lipsey MW. School-based interventions for aggressive and disruptive behavior: update of a meta-analysis. Am J Prev Med. 2007;33(suppl):S130-S143. doi:10.1016/j.amepre.207.04.01 PubMed (Pubitemid 47176842)
130. Fossum S, Handegård BH, Martinussen M, et al. Psychosocial interventions for disruptive and aggressive behaviour in children and adolescents: a meta-analysis. Eur Child Adolesc Psychiatry. 2008;17(7):438-451. doi:10.107/s0787-08-0686-8 PubMed
131. Scahill L, Leckman JF, Schultz RT, et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60(7):1130-1135. PubMed
132. Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry. 2000;39(3):292-299. doi:10.1097/04583-2030-010 PubMed (Pubitemid 30127607)
133. Piacentini J, Woods DW, Scahill L, et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA. 2010;303(19):1929-1937. doi:10.101/jama.2010.607 PubMed
134. Safer DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol. 2004;24(4):429-436. doi:10.1097/01.jcp.013058. 86125.5b PubMed (Pubitemid 38944142)
135. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45(7):771-791. doi:10.1097/01.chi.020851.94392.30 PubMed
136. Kryzhanovskaya L, Schulz SC, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(1):60-70. doi:10.1097/CHI.0b013e318190404 PubMed
137. Correll CU, Kane JM. One-year tardive dyskinesia rates in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol. 2007;17(5):647-655. doi:10.1089/cap.206.017 PubMed (Pubitemid 350058977)
138. Safety and tolerability of ziprasidone in adolescents with schizophrenia. http://clinicaltrials.gov/ct2/show/NCT00265382. Updated August 31, 2010. Accessed April 19, 2011.
139. Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165(11):1432-1441. doi:10.176/api.ajp.208.07061035 PubMed
140. Haas M, Unis AS, Armenteros J, et al. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009;19(6):611-621. doi:10.1089/cap.208.014 PubMed
141. Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009;70(10):1441- 1451. doi:10.408/JCP.09m05164yel PubMed
142. Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007;164(10):1547-1556. doi:10.176/api.ajp.207.061932 PubMed (Pubitemid 350069734)
143. DelBello MP, Findling RL, Acevedo LD, et al. Efficacy of quetiapine in children and adolescents with bipolar mania: a 3-week double-blind, randomized, placebo-controlled trial. Presented at: 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 24-29, 2007; Boston, MA.
144. Haas M, Delbello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2009;11(7):687-700. doi:10.1/j.139-5618.209.0750.x PubMed
145. DelBello MP, Findling RL, Wang PP, et al. Efficacy and safety of ziprasidone in pediatric bipolar disorder. Presented at: 63rd Annual Meeting of the Society of Biological Psychiatry; May 1-3, 2008; Washington, DC.
146. Montañés-Rada F, Gangoso-Fermoso AB, Martínez-Granero MA. Drugs for attention deficit hyperactivity disorder [in Spanish]. Rev Neurol. 2009;48(9):469-481. PubMed
147. Correll CU. Systematic review of randomized controlled trials of pharmacologic treatments for youth with maladaptive aggression and related best practice recommendations. Presented at: 57th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 26-31, 2010; New York, NY.
148. DelBello MP, Chang K, Welge JA, et al. A double-blind, placebo- controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord. 2009;11(5):483-493. doi:10.1/j.139-5618.209.0728.x PubMed
149. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001;40(2):168-179. PubMed